The FDA has granted breakthrough therapy designation status to Genentech’s rituximab (Rituxan) for pemphigus vulgaris (PV), a rare, serious, and life-threatening autoimmune disease with limited treatment options.
The designation is intended to expedite the development and review of medications with early evidence of potential clinical benefit in serious diseases and to help ensure that patients get access to these medications as soon as possible. Patients diagnosed with PV are currently being enrolled for a phase 3 trial of rituximab.
Rituximab is currently approved for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
The breakthrough status came following a review of data from a Roche-supported randomized trial conducted in France that evaluated rituximab plus oral corticosteroid treatment compared with corticosteroid as a first-line treatment in patients with moderate to severe pemphigus. (Roche markets rituximab outside the United States and Japan.) The study, which was published in The Lancet, showed that Rituxan may provide substantial improvement in disease remission rates and successful tapering and/or cessation of corticosteroid therapy.
Meanwhile, there’s been progress with developing a biosimilar for rituximab. The European Medicines Agency (EMA) is expected to soon grant approval for Celltrion’s rituximab biosimilar (Truxima). The EMA’s Committee for Medicinal Product for Human Use announced on December 16, 2016, that it had recommended granting marketing approval for rituximab biosimilar. European oncologists expect the arrival of a rituximab biosimilar to slash costs and expand patient access to the expensive oncology treatment. Europe would be the first big market for rituximab biosimilars because a US approval of biosimilar rituximab is probably farther in the future.
The rituximab biosimilar has already penetrated the Asian market—it was approved in 2016 in South Korea, covering all indications of the reference drug. In the United States, Celltrion is collaborating with Teva, which will commercialize the biosimilar if approved here.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.